Comparative Pharmacology
Head-to-head clinical analysis: FETROJA versus ROCEPHIN W DEXTROSE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FETROJA versus ROCEPHIN W DEXTROSE IN PLASTIC CONTAINER.
FETROJA vs ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefiderocol is a cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), particularly PBP3, and is stable against a broad range of beta-lactamases, including carbapenemases, due to its ability to penetrate the outer membrane via the bacterial iron transport system.
Ceftriaxone is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
1 gram intravenously over 3 hours every 8 hours in patients 18 years and older with creatinine clearance ≥ 60 mL/min.
1-2 g IV or IM once daily; maximum 4 g/day. For serious infections, 2 g IV every 12 hours.
None Documented
None Documented
Terminal elimination half-life: 2.5-3.5 hours; prolonged in renal impairment (e.g., up to 5-6 hours in severe renal impairment), requiring dose adjustment
Terminal elimination half-life: 6-8 hours in adults with normal renal function; prolonged up to 15 hours in elderly; significantly increased in renal impairment (up to 20-30 hours in ESRD).
Renal: approximately 65-70% of the dose excreted unchanged in urine; biliary/fecal: minimal (<1%)
Renal (33-67% unchanged) and biliary (40-50% unchanged and microbiologically inactive metabolite). Approximately 50% excreted in urine, 50% in feces.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic